Effectiveness and safety of first-line ipilimumab (IPI) 3mg/kg therapy for advanced melanoma (AM): Evidence from a U.S. multisite retrospective chart review — ASN Events
  1. Schedule
  2. Posters - Clinical research
  3. Effectiveness and safety of first-line ipilimumab (IPI) 3mg/kg therapy for advanced melanoma (AM): Evidence from a U.S. multisite retrospective chart review

Effectiveness and safety of first-line ipilimumab (IPI) 3mg/kg therapy for advanced melanoma (AM): Evidence from a U.S. multisite retrospective chart review (#194)

Kim A Margolin 1 , Schiffon L Wong 2 , John R Penrod 2 , Jingli Song 3 , I-Fen Chang 2 , Tony Hebden 2 , Douglas B Johnson 4 , Sekwon Jang 5 , Joseph Clark 6 , David McDermott 7
  1. University of Washington, Seattle, WA, United States of America
  2. Bristol-Myers Squibb, Plainsboro, NJ, United States of America
  3. Bristol-Myers Squibb, Wallingford, CT, United States
  4. Vanderbilt University Medical Center, Nashville, TN, United States of America
  5. Washington Cancer Institute, MedStar Health Washington Hospital Center, Washington DC, United States of America
  6. Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, IL, United States of America
  7. Beth Israel Deaconess Medical Center, Boston, MA, United States of America
Publish consent withheld